Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158565526> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2158565526 endingPage "iii29" @default.
- W2158565526 startingPage "iii29" @default.
- W2158565526 abstract "Introduction: In addition to established clinicopathological prognostic factors, genomic multigene assays may assist adjuvant treatment decisions in breast cancer. EndoPredict (EP) is a novel multigene assay to predict the risk of metastasis in patients with estrogen receptor (ER) positive, HER-2 negative breast cancer treated with endocrine therapy alone. It is performed decentralized in pathology laboratories and combines a molecular 8-gene score with clinical data (EPclin score). It provides additional prognostic information compared to standard pathological and clinical factors alone. We investigated the performance of EPclin in clinical practice and performed a retrospective evaluation of its impact of on treatment decision. Materials and methods: All EPs that were performed during a period of one year at the Department of Pathology of the Charité were evaluated. Clinical and pathological data were extracted from pathology reports. For evaluation of treatment decisions, a questionnaire was sent to the participating gynecologists. It consisted of two questions with two possible answers regarding treatment decision before and after the EP. Results: 167 tests were successfully performed, 58.8 % in three days or less. 77 patients (46.4 %) were classified as low risk and 89 (53.6 %) as high risk. The estimated median 10-year-risk for metastasis with endocrine therapy alone was 11%. We received questionnaires for 130 patients (77.8 %). Therapy recommendation was changed in 37.7 % of cases after the EP. 16 patients (12.3 %) received additional chemotherapy while 33 (25.4 %) cases were reconsidered to receive endocrine therapy alone. 8 patients (6.1 %) did not agree to the recommendation of the tumor board. Conclusions: The EndoPredict assay is applicable in daily practice in a molecular pathology laboratory. It markedly changes treatment decisions in ER positive breast cancer. Disclosure: M. Dietel: Shareholder: Sividon Diagnostics C. Denkert: Shareholder: Sividon Diagnostics All other authors have declared no conflicts of interest." @default.
- W2158565526 created "2016-06-24" @default.
- W2158565526 creator A5008672227 @default.
- W2158565526 creator A5010080708 @default.
- W2158565526 creator A5022667115 @default.
- W2158565526 creator A5033698551 @default.
- W2158565526 creator A5055235683 @default.
- W2158565526 creator A5055724880 @default.
- W2158565526 creator A5059885667 @default.
- W2158565526 creator A5062227589 @default.
- W2158565526 creator A5066471672 @default.
- W2158565526 date "2013-05-01" @default.
- W2158565526 modified "2023-10-01" @default.
- W2158565526 title "A Novel Multigene Assay in Clinical Practice - Performance and Impact On Clinical Decisions" @default.
- W2158565526 doi "https://doi.org/10.1093/annonc/mdt084.17" @default.
- W2158565526 hasPublicationYear "2013" @default.
- W2158565526 type Work @default.
- W2158565526 sameAs 2158565526 @default.
- W2158565526 citedByCount "1" @default.
- W2158565526 countsByYear W21585655262019 @default.
- W2158565526 crossrefType "journal-article" @default.
- W2158565526 hasAuthorship W2158565526A5008672227 @default.
- W2158565526 hasAuthorship W2158565526A5010080708 @default.
- W2158565526 hasAuthorship W2158565526A5022667115 @default.
- W2158565526 hasAuthorship W2158565526A5033698551 @default.
- W2158565526 hasAuthorship W2158565526A5055235683 @default.
- W2158565526 hasAuthorship W2158565526A5055724880 @default.
- W2158565526 hasAuthorship W2158565526A5059885667 @default.
- W2158565526 hasAuthorship W2158565526A5062227589 @default.
- W2158565526 hasAuthorship W2158565526A5066471672 @default.
- W2158565526 hasBestOaLocation W21585655261 @default.
- W2158565526 hasConcept C121608353 @default.
- W2158565526 hasConcept C126322002 @default.
- W2158565526 hasConcept C143998085 @default.
- W2158565526 hasConcept C167135981 @default.
- W2158565526 hasConcept C1862650 @default.
- W2158565526 hasConcept C207886595 @default.
- W2158565526 hasConcept C2776694085 @default.
- W2158565526 hasConcept C2779013556 @default.
- W2158565526 hasConcept C2779974597 @default.
- W2158565526 hasConcept C29456083 @default.
- W2158565526 hasConcept C530470458 @default.
- W2158565526 hasConcept C71924100 @default.
- W2158565526 hasConceptScore W2158565526C121608353 @default.
- W2158565526 hasConceptScore W2158565526C126322002 @default.
- W2158565526 hasConceptScore W2158565526C143998085 @default.
- W2158565526 hasConceptScore W2158565526C167135981 @default.
- W2158565526 hasConceptScore W2158565526C1862650 @default.
- W2158565526 hasConceptScore W2158565526C207886595 @default.
- W2158565526 hasConceptScore W2158565526C2776694085 @default.
- W2158565526 hasConceptScore W2158565526C2779013556 @default.
- W2158565526 hasConceptScore W2158565526C2779974597 @default.
- W2158565526 hasConceptScore W2158565526C29456083 @default.
- W2158565526 hasConceptScore W2158565526C530470458 @default.
- W2158565526 hasConceptScore W2158565526C71924100 @default.
- W2158565526 hasLocation W21585655261 @default.
- W2158565526 hasOpenAccess W2158565526 @default.
- W2158565526 hasPrimaryLocation W21585655261 @default.
- W2158565526 hasRelatedWork W2348231456 @default.
- W2158565526 hasRelatedWork W2354050160 @default.
- W2158565526 hasRelatedWork W2367105124 @default.
- W2158565526 hasRelatedWork W2367923615 @default.
- W2158565526 hasRelatedWork W2370228045 @default.
- W2158565526 hasRelatedWork W2379009234 @default.
- W2158565526 hasRelatedWork W2379151083 @default.
- W2158565526 hasRelatedWork W2388730008 @default.
- W2158565526 hasRelatedWork W2782589310 @default.
- W2158565526 hasRelatedWork W2791179561 @default.
- W2158565526 hasVolume "24" @default.
- W2158565526 isParatext "false" @default.
- W2158565526 isRetracted "false" @default.
- W2158565526 magId "2158565526" @default.
- W2158565526 workType "article" @default.